Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection
The severe acute respiratory syndrome virus (SARS-CoV-2), a novel coronavirus first discovered in Wuhan, China in December 2019 causes the Coronavirus Disease 19 (COVID-19), which presents with a wide range of clinical symptoms from mild or moderate to severe and critical illnesses. With the conti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Journal of Pure and Applied Microbiology
2020-05-01
|
| Series: | Journal of Pure and Applied Microbiology |
| Subjects: | |
| Online Access: | https://microbiologyjournal.org/current-status-of-treatment-options-clinical-trials-and-vaccine-development-for-sars-cov-2-infection/ |
| _version_ | 1818398149747671040 |
|---|---|
| author | Ran Jing Rama Rao Vunnam Yuhong Yang Adam Karevoll Srinivas Rao Vunnam |
| author_facet | Ran Jing Rama Rao Vunnam Yuhong Yang Adam Karevoll Srinivas Rao Vunnam |
| author_sort | Ran Jing |
| collection | DOAJ |
| description | The severe acute respiratory syndrome virus (SARS-CoV-2), a novel coronavirus first discovered in
Wuhan, China in December 2019 causes the Coronavirus Disease 19 (COVID-19), which presents with a wide range of clinical symptoms from mild or moderate to severe and critical illnesses. With the
continuing transmission of the virus worldwide and the rapidly evolving situation globally, the World
Health Organization (WHO) declared the COVID-19 outbreak a pandemic in March. Currently, there
is no proven specific treatment for this potentially deadly disease beyond supportive care. However,
a massive effort has been put globally into the investigation of medications and other interventional
measures to fight COVID-19. Convalescent plasma therapy from recovered patients has recently drawn
considerable interest. Several alternative medical treatments, although evidence of their efficacy still
lacking, have also gained popularity, especially in countries with such traditions such as India and China.
Rapid repurposing of drugs for COVID-19 has revealed a few promising candidate antiviral agents, but
further research, especially high quality randomized controlled trials, will be needed to prove their
efficacy and safety in the clinical use to treat COVID-19. Vaccine development has been the imperative
task in the battle against SARS-CoV-2. While clinical trials have been launched for several candidate
vaccines, research on COVID-19 vaccines is still at an early stage. So far, optimized supportive care
remains the best practice against COVID-19. |
| first_indexed | 2024-12-14T07:00:12Z |
| format | Article |
| id | doaj.art-fc4ad1aedc6145ec8a9eea5e4c23a18d |
| institution | Directory Open Access Journal |
| issn | 0973-7510 2581-690X |
| language | English |
| last_indexed | 2024-12-14T07:00:12Z |
| publishDate | 2020-05-01 |
| publisher | Journal of Pure and Applied Microbiology |
| record_format | Article |
| series | Journal of Pure and Applied Microbiology |
| spelling | doaj.art-fc4ad1aedc6145ec8a9eea5e4c23a18d2022-12-21T23:12:27ZengJournal of Pure and Applied MicrobiologyJournal of Pure and Applied Microbiology0973-75102581-690X2020-05-0114suppl 173374010.22207/JPAM.14.SPL1.10Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 InfectionRan Jing0https://orcid.org/0000-0002-3037-8982Rama Rao Vunnam1https://orcid.org/0000-0001-9431-7997Yuhong Yang2https://orcid.org/0000-0003-4115-0681Adam Karevoll3https://orcid.org/0000-0002-6023-4891Srinivas Rao Vunnam4https://orcid.org/0000-0002-3264-0825University of Nebraska College of Medicine, 985520 Nebraska Medical Center, Omaha, NE 68198, USA. Penn State College of Medicine, 700 HMC Crescent Road, Hershey, PA 17033, USA.University of Nebraska College of Medicine, 985520 Nebraska Medical Center, Omaha, NE 68198, USA. University of Nebraska College of Medicine, 985520 Nebraska Medical Center, Omaha, NE 68198, USA. University of Nebraska College of Medicine, 985520 Nebraska Medical Center, Omaha, NE 68198, USA. The severe acute respiratory syndrome virus (SARS-CoV-2), a novel coronavirus first discovered in Wuhan, China in December 2019 causes the Coronavirus Disease 19 (COVID-19), which presents with a wide range of clinical symptoms from mild or moderate to severe and critical illnesses. With the continuing transmission of the virus worldwide and the rapidly evolving situation globally, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic in March. Currently, there is no proven specific treatment for this potentially deadly disease beyond supportive care. However, a massive effort has been put globally into the investigation of medications and other interventional measures to fight COVID-19. Convalescent plasma therapy from recovered patients has recently drawn considerable interest. Several alternative medical treatments, although evidence of their efficacy still lacking, have also gained popularity, especially in countries with such traditions such as India and China. Rapid repurposing of drugs for COVID-19 has revealed a few promising candidate antiviral agents, but further research, especially high quality randomized controlled trials, will be needed to prove their efficacy and safety in the clinical use to treat COVID-19. Vaccine development has been the imperative task in the battle against SARS-CoV-2. While clinical trials have been launched for several candidate vaccines, research on COVID-19 vaccines is still at an early stage. So far, optimized supportive care remains the best practice against COVID-19.https://microbiologyjournal.org/current-status-of-treatment-options-clinical-trials-and-vaccine-development-for-sars-cov-2-infection/covid-19sars-cov-2supportive careclinical trialsvaccine |
| spellingShingle | Ran Jing Rama Rao Vunnam Yuhong Yang Adam Karevoll Srinivas Rao Vunnam Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection Journal of Pure and Applied Microbiology covid-19 sars-cov-2 supportive care clinical trials vaccine |
| title | Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection |
| title_full | Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection |
| title_fullStr | Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection |
| title_full_unstemmed | Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection |
| title_short | Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection |
| title_sort | current status of treatment options clinical trials and vaccine development for sars cov 2 infection |
| topic | covid-19 sars-cov-2 supportive care clinical trials vaccine |
| url | https://microbiologyjournal.org/current-status-of-treatment-options-clinical-trials-and-vaccine-development-for-sars-cov-2-infection/ |
| work_keys_str_mv | AT ranjing currentstatusoftreatmentoptionsclinicaltrialsandvaccinedevelopmentforsarscov2infection AT ramaraovunnam currentstatusoftreatmentoptionsclinicaltrialsandvaccinedevelopmentforsarscov2infection AT yuhongyang currentstatusoftreatmentoptionsclinicaltrialsandvaccinedevelopmentforsarscov2infection AT adamkarevoll currentstatusoftreatmentoptionsclinicaltrialsandvaccinedevelopmentforsarscov2infection AT srinivasraovunnam currentstatusoftreatmentoptionsclinicaltrialsandvaccinedevelopmentforsarscov2infection |